BioCentury
ARTICLE | Financial News

ApoGen expands series A to $11M

August 31, 2018 6:13 PM UTC

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is the venture arm of Merck KGaA (Xetra:MRK).

Keno Gutierrez, an investment director at M Ventures, joined ApoGen’s board...